Company news
Altimmune, Inc. (NASDAQ:ALT) news
Every Altimmune, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
August 12, 2026
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
August 5, 2026
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
August 3, 2026
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
July 30, 2026
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
July 28, 2026
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
July 7, 2026
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
May 28, 2026
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regressio...
May 27, 2026
Altimmune Announces First Quarter 2026 Financial Results and Business Update
May 13, 2026
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
May 13, 2026
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
May 6, 2026
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
April 27, 2026
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
April 22, 2026
Altimmune Announces Proposed Underwritten Public Offering of Securities
April 22, 2026
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
March 5, 2026
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
February 26, 2026
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
January 29, 2026
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
January 27, 2026
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
January 5, 2026
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
December 19, 2025
Altimmune Announces CEO Transition and Succession Plan
December 1, 2025
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The L...
November 11, 2025
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poste...
November 7, 2025
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
November 6, 2025
Altimmune to Participate in Two Upcoming Investor Conferences
November 5, 2025
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
November 3, 2025
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
October 30, 2025
Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AA...
October 20, 2025
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Developme...
September 29, 2025
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Developme...
September 29, 2025
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
September 15, 2025
Altimmune to Participate in Upcoming Investor Conferences
August 26, 2025
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
August 19, 2025
Altimmune Announces Second Quarter 2025 Financial Results and Business Update
August 12, 2025
Altimmune Board of Directors Appoints Jerry Durso as Chairman
August 11, 2025
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
August 5, 2025
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Dis...
July 9, 2025
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
June 26, 2025
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
June 25, 2025
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
June 13, 2025
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
May 19, 2025
Altimmune to Participate at Two Upcoming Investor Conferences
May 14, 2025
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
May 13, 2025
Altimmune Announces First Quarter 2025 Financial Results and Business Update
May 13, 2025
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL Internatio...
May 8, 2025
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
May 6, 2025
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
May 1, 2025
Altimmune to Participate in the Citizens Life Sciences Conference
April 30, 2025
Altimmune to Host Virtual R&D Day on March 13, 2025
March 6, 2025